Silver Book Fact

It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.

Tapp R, Shaw J, Harper C, P de Courten M, et al. The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population. Diabetes Care. 2003; 26(6): 1731-1737. http://care.diabetesjournals.org/content/26/6/1731

Reference

Title
The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population
Publication
Diabetes Care
Publication Date
2003
Authors
Tapp R, Shaw J, Harper C, P de Courten M, et al
Volume & Issue
Volume 26, Issue 6
Pages
1731-1737
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • Remote Interpretation of Retinal Imaging for DR
    Use of remote interpretation of retinal imaging in diabetics sent via tele-ophthalmology, improved the frequency of screening from 32% to 71% in only 12 months.